Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (1.852%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 27.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Bank of Cyprus swings profit; Sareum loss widens

Mon, 21st Feb 2022 18:13

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Bank of Cyprus Holdings PLC - Nicosia-based lender - Reports turnover of EUR755.2 million for 2021, down from EUR765.1 million in 2020. Despite this, swings to pretax profit of EUR36.1 million from loss of EUR166.9 million. Is helped by sharply reduced credit losses to cover credit risk on loans and advances to customers, booking expense of EUR40.3 million in 2021 versus charge of EUR275.1 million in 2020. "2021 saw a strong recovery in the Cypriot economy after a period of pandemic-related disruption, providing an improved backdrop against which the Bank performed well. During the year we continued to support the country's return to growth, extending EUR1.8 bn of new loans, an increase of a third on the prior year and steadily recovering towards pre-pandemic levels," says Chief Executive Panicos Nicolaou. Looking ahead, now targets return on tangible equity in medium-term in excess of 10%, "providing the foundations for a return of dividend distributions, subject to performance and relevant approvals."

----------

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Pretax loss for six months to December 31 widens to GBP1.0 million from GBP610,000 year-on-year, with no revenue generated in either period. Says it is looking to 2022 with optimism and expects to report on continued progress both with its proprietary programmes, in particular the advancement of SDC-1801 into clinical trials, and with partnered asset, SRA737, should Sierra advance its development. "The board and management also continue to employ rigorous capital allocation in the development of internal assets and the overall business, with a clear focus on generating value for shareholders," firm says.

----------

Sylvania Platinum Ltd - Bermuda-based platinum group metals producer - Revenue for six months to end of December falls to USD69.1 million from USD84.9 million, while pretax profit drops to USD34.9 million from USD57.4 million. Sylvania Dump Operations delivered 32,376 4E PGM ounces, down from 36,335 ounces a year ago. Notes lower than planned run of mine and current arising PGM feed grades at the Western operations affected production, as well as temporary suspension of operations at Lesedi extended through the first quarter and, subsequent to start-up, the plant incurred further downtime related to general water shortages at the Western operations during the second quarter. Declares windfall dividend of 2.25 pence, to be paid in April. "Based on the progress that we are making with the Lesedi MF2, which we plan to commission in March, as well as the provisional results from targeted sampling campaigns and investigations to evaluate potential alternative feed sources to mitigate current low ROM feed grades at Mooinooi, we are expecting a stronger production performance during HY2 FY2022," says Chief Executive Jaco Prinsloo.

----------

Graft Polymer (UK) PLC - Slovenia-based polymer modification and drug delivery systems - Expects an increase in commercial orders following successful trials. To meet demand, firm has moved to a two-shift operation at its Slovenia production facility to ensure order fulfilment. Full production capacity at the existing facilities is results in an output of 4,000 tonnes of product per year. "This is in line with the strategy of investing in additional equipment at its facility to increase the production capabilities as set out in the IPO prospectus. These investments will allow the Company to increase its current production output to 6,000 tonnes per annum," firm says. Adds that Slovenian Intellectual Property Office has awarded company four new patents.

----------

Cellular Goods PLC - London-based cannabinoid product company - After strategy review, says it will exclusively focus on wellness products across its three market verticals, being skincare, supplements and recovery. Says initial sales of inaugural products have been below internal forecasts due to "market challenges". "The company has identified various factors that negatively impacted sales, including a policy decision by some of the world's largest social media companies. Google, and Meta's platforms Facebook and Instagram, prohibit advertising cannabis-derived products, which has prevented the company's products from being promoted there," firm says. Has made changes to media mix for its upcoming marketing campaign. Says it has accelerated retail partnerships and has launched Look Better range on Amazon Marketplace.

----------

Immotion Group PLC - Manchester, England-based virtual reality entertainment company - Says second half revenue was around GBP6.6 million, more than double the GBP2.8 million in the first half of the year. Second half operating cash inflow was strong, with year-end cash on hand of GBP1.1 million, almost double the GBP600,000 at the half year. "Overall, we feel we have made good progress across the company and are looking forward with renewed confidence," says Chief Executive Martin Higginson. Adds that it has got contract extension and expansion of capacity at Shark Reef Aquarium, inside Mandalay Bay Resort & Casino, Las Vegas, currently the group's largest installation. This will see the theatre capacity increase to 48 seats from its current 36 seats, and the contract will be extended by a further 12 months through to January 31, 2024. Says that in addition, capacity at another two of its strongest performing sites has been "significantly expanded".

----------

Allied Minds PLC - Boston, Massachusetts-based intellectual property commercialisation company - Says portfolio company Federated Wireless has secured USD58 million in Series D funding at a pre new-money valuation of USD230 million. Allied Minds participates in fundraise, alongside an affiliate of Cerberus Capital Management LP and GIC, Singapore's sovereign wealth fund. "We're proud of the achievements made by Federated Wireless, which have been recognised by investors in this well-backed funding round," says Chair Harry Rein. Adds that Mark Pritchard, founder and former executive chair of Allied Minds and a 5.5% shareholder, has been appointed as a consultant to the board.

----------

BiVictriX Therapeutics PLC - Macclesfield, England-based drug development company specialising in cancer treatments - Files four new patent applications in the UK related to several novel cancer-specific antigen pairs or "fingerprints" across a range of oncology indications. These applications focus on three novel cancer-specific antigen fingerprints that have been identified by the company and can support the development of a pipeline of highly selective cancer therapeutics utilising the company's Bi-Cygni approach. "These filings are the next step in the company's strategy to broaden its patent portfolio both in the UK and internationally," it says.

----------

Polar Capital Global Financials Trust PLC - London-based financial investor - Plans to raise additional funds through share issue as interest in company "remains high" and appetite for shares "has not diminished". To issue new shares at a placing price to be published on the day following the closing date of the placing. "The directors and Polar Capital LLP continue to believe that the company is well positioned to benefit from higher interest rates, rising inflation expectations and stronger economic growth given the significant exposure of the portfolio to banks in particular," firm says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
5 May 2023 15:53

Sareum gets approval for phase one psoriasis studies in Australia

(Sharecast News) - Biotechnology developer Sareum Holdings announced on Friday that it has been granted approval by Australia's Therapeutic Goods Administration (TGA) to conduct phase one clinical studies on SDC-1801.

Read more
5 May 2023 11:26

Sareum receives Australian approval for psoriasis drug clinical trial

Alliance News) - Sareum Holdings PLC on Friday said its application to start a phase 1 clinical trial in Australia of its lead product, psoriasis drug SDC-1801, has been approved.

Read more
5 May 2023 11:11

AIM WINNERS & LOSERS: Aptamer says struggling to convert pipeline

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
22 Mar 2023 11:47

Sareum Holdings interim loss widens as touts psoriasis candidate drug

(Alliance News) - Sareum Holdings PLC on Wednesday reported an increased half-year loss for the six months to December 31, as it continued to work on its psorasis candidate drug SDC-1801.

Read more
17 Mar 2023 18:06

IN BRIEF: Sareum makes trial application for SDC-1801 in Australia

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune disease and cancer - On Wednesday, says it has begun an application to perform phase one clinical studies on SDC-1801 in Australia under the clinical trial notification scheme.

Read more
15 Mar 2023 15:43

UK earnings, trading statements calendar - next 7 days

Thursday 16 March 
Capital LtdFull Year Results
Centamin PLCFull Year Results
Deliveroo PLCFull Year Results
DFS Furniture PLCHalf Year Results
Empiric Student Property PLCFull Year Results
Eurocell PLCFull Year Results
FW ThorpeHalf Year Results (TBC)
Gelion PLCHalf Year Results
Gem Diamonds LtdFull Year Results
Gym Group PLCFull Year Results
Halma PLCTrading Statement
Helios Towers PLCFull Year Results
Hostmore PLCFull Year Results
Investec PLC and LtdTrading Statement
National World PLCFull Year Results
OSB Group PLCFull Year Results
PensionBee Group PLCFull Year Results
Polymetal International PLCfull Year Results
PYX Resources LtdFull Year Results
Rentokil Initial PLCFull Year Results
Restore PLCFull Year Results
Savills PLCFull Year Results
TI Fluid Systems PLCFull Year Results
WAG Payment Solutions PLCFull Year Results
Friday 17 March 
no events scheduled 
Monday 20 March 
Jubilee Metals Group PLCHalf Year Results
Tuesday 21 March 
Alliance Pharma PLCFull Year Results
Aptitude Software Group PLCFull Year Results
Boku IncFull Year Results
Diversified Energy Co PLCFull Year Results
Ergomed PLCFull Year Results
Fintel PLCFull Year Results
Gamma Communications PLCFull Year Results
Henry Boot PLCFull Year Results
Kape Technologies PLCFull Year Results
Kingfisher PLCFull Year Results
Luceco PLCFull Year Results
MP Evans Group PLCFull Year Results
Ocado Group PLCTrading Statement
Oxford Nanopore Technologies PLCFull Year Results
Pebble Group PLCFull Year Results
Quixant PLCFull Year Results
ScS Group PLCHalf Year Results
SThree PLCTrading Statement
Staffline Group PLCFull Year Results
Tissue Regenix Group PLCFull Year Results
Trustpilot Group PLCFull Year Results
YouGov PLCHalf Year Results
Zotefoams PLCFull Year Results
Wednesday 22 March 
Anpario PLCFull Year Results
Atalaya Mining PLCFull Year Results
BioPharma Credit PLCFull Year Results
Blackbird PLCFull Year Results
Bloomsbury Publishing PLCTrading Statement
Essentra PLCFull Year Results
Fevertree Drinks PLCFull Year Results
Genel Energy PLCFull Year Results
Gresham House PLCFull Year Results
Hostelworld Group PLCFull Year Results
Judges Scientific PLCFull Year Results
Kenmare Resources PLCFull Year Results
LSL Property Services PLCFull Year Results
Mpac Group PLCFull Year Results
NAHL Group PLCFull Year Results
Pendragon PLCFull Year Results
Pharos Energy PLCFull Year Results
Sareum Holdings PLCHalf Year Results
Ten Entertainment Group PLCFull Year Results
Tribal Group PLCFull Year Results
Vistry Group PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
6 Mar 2023 16:16

Sareum looks at options as GSK division returns cancer drug candidate

(Sharecast News) - Biotechnology developer Sareum announced on Monday that GSK subsidiary Sierra Oncology has returned clinical study reports and associated documents related to 'SRA737' to Sareum's co-development partner, the CRT Pioneer Fund.

Read more
6 Mar 2023 11:19

Sareum says GSK's Sierra returns clinical study reports to CRT Pioneer

(Alliance News) - Sareum Holdings PLC on Monday said that GSK PLC subsidiary Sierra Oncology Inc has completed the return of the clinical study reports relating to SRA737 to Sarerum's co-development partner CRT Pioneer Fund LP.

Read more
16 Dec 2022 21:53

TRADING UPDATES: Dev Clever to cancel shares; Tintra raises funds

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
16 Dec 2022 16:55

Sareum confident despite recent setbacks

(Sharecast News) - Autoimmune and cancer-focussed biotechnology company Sareum said in an update on Friday that it remained "confident" despite some recent setbacks.

Read more
16 Dec 2022 10:44

AIM WINNERS & LOSERS: Time Finance jumps on strong first-half results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
9 Dec 2022 15:43

UK shareholder meetings calendar - next 7 days

Monday 12 December 
Devolver Digital IncSGM re 2022 Long-Term Incentive Plan approval
Marwyn Value Investors LtdAGM
Osirium Technologies PLCGM re placing agreement with Allenby Capital
PCF Group PLCGM re proposed cancellation of trading on AIM
Tuesday 13 December 
Amedeo Air Four Plus LtdAGM
Avation PLCAGM
Blancco Technology Group PLCAGM
JD Sports Fashion PLCGM re remuneration policy
Macau Property Opportunities Fund LtdAGM
Softcat PLCAGM
Spectris PLCGM re remuneration policy
Wednesday 14 December 
Fidelity Special Values PLCAGM
Kistos PLCGM re new non-operational entity
Parsley Box Group PLCGM re proposal to become a private limited company
TP Group PLCGM re cash acquisition
Volution Group PLCAGM
Westpac Banking CorpAGM
Thursday 15 December 
Aeorema Communications PLCAGM
Argos Resources LtdAGM
Baillie Gifford Japan Trust PLCAGM
Capricorn Energy PLCGM re proposed share premium account cancellation
Chelverton Growth Trust PLCAGM
CQS Natural Resources Growth & Income PLCAGM
DX Group PLCAGM
DXS International PLCAGM
Glenveagh Properties PLCEGM
Secured Income Fund PLCGM re proposed reduction of capital
Schroder Income Growth Fund PLCAGM
Friday 16 December 
Bellway PLCAGM
Inchcape PLCGM re Derco acquisition
JPMorgan Global Growth & Income PLCGM re proposed combination with JPMorgan Elect PLC
National Australia Bank LtdAGM
Sareum Holdings PLCAGM
Thor Explorations LtdAGM
UP Global Sourcing Holdings PLCAGM
  
Copyright 2022 Alliance News Ltd. All Rights Reserved.

Read more
21 Nov 2022 12:44

IN BRIEF: Sareum salutes publication of SRA737 combination trial data

Sareum Holdings PLC - Cambridge, England-based biotechnology company focused on developing kinase inhibitors for autoimmune disease & cancer - Says it is pleased by the publication of data from the Phase 1/2 trial of SRA737 as a combination treatment for advanced cancers in the medical journal, Clinical Cancer Research.

Read more
24 Oct 2022 10:28

IN BRIEF: Sareum widens annual loss; considers future of SRA737

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - In the year ended June 30, pretax loss widens to GBP2.6 million from GBP1.7 million a year before. No revenue is recorded in either year, but in the previous year it brought in GBP171,000 in other operating income, with none recorded for financial 2022. Says it will discuss the future of SRA737 with partner Cancer Research Technology Pioneer Fund. Earlier this month, GSK PLC subsidiary Sierra Oncology Inc said it intends to return the rights for the SRA737 cancer treatment to CPF.

Read more
12 Oct 2022 10:47

Sareum plunges as GSK subsidiary Sierra returns rights for SRA737

(Alliance News) - Sareum Holdings PLC on Wednesday after Sierra Oncology Inc, a subsidiary of GSK PLC, said it intends to return the rights for SRA737 to the CRT Pioneer Fund LP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.